Bright Minds Biosciences (DRUG) Cash from Restructuring (2022 - 2026)
Bright Minds Biosciences' (DRUG) quarterly Cash from Restructuring came in at -$19154.8 in Q1 2026, down 211.59% YoY from $17165.1 in Q1 2025, and down 2.64% on a QoQ basis from -$18662.2 in Q4 2025.
Bright Minds Biosciences (DRUG) Cash from Restructuring (2022 - 2026) Analysis & Trends
Bright Minds Biosciences (DRUG) has 5 years of Cash from Restructuring data on file, last reported at -$19154.8 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Bright Minds Biosciences | 733.05 Mn | 733.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19,154.78 |
| Dec 31, 2025 | -18,662.17 |
| Jun 30, 2025 | -88,380.91 |
| Mar 31, 2025 | 17,165.05 |
| Dec 31, 2024 | 17,030.05 |
| Jun 30, 2024 | 16,053.65 |
| Mar 31, 2024 | 16,294.58 |
| Dec 31, 2023 | 16,128.20 |
| Jun 30, 2023 | 15,997.54 |
| Mar 31, 2023 | 15,896.07 |
| Dec 31, 2022 | 15,830.27 |